Jefferies Group LLC Atara Biotherapeutics, Inc. Transaction History

Jefferies Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $31,395 - $96,169	-11,016 Reduced 15.74%	58,984 $11,000
Q2 2022 Sep 21, 2023	BUY	$4.69 - $9.84 $51,665 - $108,397	11,016 Added 18.68%	70,000 $545,000
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $328,300 - $688,800	70,000 New	70,000 $545,000
Q1 2020 May 15, 2020	SELL	$5.69 - $17.78 $76,598 - $239,354	-13,462 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$10.89 - $16.79 $4,769 - $7,354	-438 Reduced 3.15%	13,462 $222,000

Q3 2019 Nov 13, 2019	BUY	$12.03 - $19.94 $158,014 - $261,911	13,135 Added 1716.99%	13,900 $196,000
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $14,573 - $31,395	765 New	765 $15,000
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $908,601 - $1.13 Million	-25,923 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$35.15 - $51.45 $907,256 - $1.33 Million	25,811 Added 23045.54%	25,923 $953,000
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $2,016 - $5,415	112 New	112 $4,000

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.